A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer

被引：0
|
作者：
Yasushi Sato
Hiroyuki Ohnuma
Masahiro Hirakawa
Minoru Takahashi
Takahiro Osuga
Yutaka Okagawa
Kazuyuki Murase
Kohichi Takada
Yutaka Kawano
Satoshi Iyama
Tsuyoshi Hayashi
Tsutomu Sato
Koji Miyanishi
Rishu Takimoto
Masayoshi Kobune
Kenji Okita
Toru Mizuguchi
Tomohisa Furuhata
Koichi Hirata
Junji Kato
机构：
[1] Sapporo Medical University School of Medicine,Department of Medical Oncology and Hematology
[2] Sapporo Kyoritsu Gorinbashi Hospital,Division of Gastroenterology
[3] Sapporo Medical University School of Medicine,Department of Surgery, Surgical Oncology and Science
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Bevacizumab; Capecitabine; Colorectal cancer; Irinotecan; Oxaliplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：587 / 594
页数：7
相关论文
共 50 条
  • [31] Capecitabine Plus Bevacizumab as First-Line Therapy for Patients with Metastatic Colorectal Cancer and Poor Performance Status
    Yamada, Yasufumi
    Yoshimatsu, Kazuhiko
    Yokomizo, Hajime
    Okayama, Sachiyo
    Satake, Masaya
    Ida, Arika
    Maeda, Hiroyuki
    Shiozawa, Shunichi
    [J]. JOURNAL OF NIPPON MEDICAL SCHOOL, 2021, 88 (05) : 496 - 499
  • [32] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
    Semir, Beslija
    Maja, Banjin
    Nadja, Paraganlija
    Timur, Ceric
    Anes, Pasic
    Berisa, Salkic
    Anes, Sosevic
    Nermina, Obralic
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [33] Impact of the addition of bevacizumab, oxaliplatin or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
    Landre, Thierry
    Aparicio, Thomas
    Ghebriou, Djamel
    Nicolas, Patrick
    Taleb, Cherifa
    Chouahnia, Kader
    Zelek, Laurent H.
    Des Guetz, Gaetan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
    Pander, Jan
    van Huis-Tanja, Lieke
    Bohringer, Stefan
    van der Straaten, Tahar
    Gelderblom, Hans
    Punt, Cornelis
    Guchelaar, Henk-Jan
    [J]. PLOS ONE, 2015, 10 (07):
  • [35] Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
    Cassinello, J.
    Alvarez, J. V.
    Garcia-Lopez, M. J.
    Pujol, E.
    Colmenarejo, A.
    De Segovia, F.
    Marcos, F.
    Filipovich, E.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 200
  • [36] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    J Barriuso
    [J]. British Journal of Cancer, 2011, 104 : 226 - 226
  • [37] Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
    M J Molina-Garrido
    C Guillén-Ponce
    [J]. British Journal of Cancer, 2011, 104 : 224 - 225
  • [38] Comment on 'Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'
    Molina-Garrido, M. J.
    Guillen-Ponce, C.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 224 - 225
  • [39] Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
    Bazarbashi, Shouki
    Aljubran, Ali
    Alzahrani, Ahmad
    Mohieldin, Ahmed
    Soudy, Hussein
    Shoukri, Mohammed
    [J]. CANCER MEDICINE, 2015, 4 (10): : 1505 - 1513
  • [40] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Barriuso, J.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 226 - 226
12345